Cytosorbents (CTSO) Q1 2026 Earnings Transcript
Cytosorbents (CTSO) reported Q1 2026 revenue of $8.9 million, up 2% YoY, with direct international markets (excluding Germany) up 13% while Germany declined. Gross margin fell to 69% from 71%. Adjusted EBITDA loss narrowed to $2.2 million (vs. $2.7 million), as operating expenses dropped to $9.2 million. Net loss was $5.1 million ($0.08/share). FDA said DrugSorb-ATR needs additional non-clinical data and real-world evidence for a de novo submission, likely pushing timing to late 2026/early 2027.
How this was made
The 30-second read
Why it matters
Q1 results show improving operating efficiency and cash burn, while FDA’s direction adds non-clinical and real-world evidence requirements that likely extend the de novo submission/approval window. STAR-T trial data supports clinical efficacy for severe bleeding reduction in urgent cardiac surgery, strengthening the commercial case for Brilinta and potentially DOAC removal label expansion.
Market read
Traders should weigh improved cost discipline and compelling STAR-T efficacy against a longer FDA timeline and near-term margin pressure from production slowdown.
What to watch
Gross margin decline is attributed to inventory/working-capital actions; if production normalization occurs faster than expected, margin could rebound sooner than the transcript implies.
Background
CytoSorb is commercially available internationally (outside US/Canada), while DrugSorb-ATR is investigational and pursuing a US de novo pathway.
Ticker impact
CTSO reported Q1 2026 results and disclosed FDA guidance for DrugSorb-ATR’s de novo path, plus STAR-T trial outcomes and cash-burn updates.
Near-term volatility likely: positive read-through from STAR-T efficacy and cost/cash discipline, offset by FDA timeline delay and margin pressure from production slowdown.
The article contains specific, decision-relevant datapoints (Q1 financials, FDA de novo direction, planned pre-submission, and trial efficacy) that directly affect CTSO’s growth and regulatory risk profile.
Market effects
Reinforces FDA’s scrutiny level for device de novo submissions requiring additional mechanistic and real-world evidence, potentially raising perceived regulatory bar for similar blood-purification/adjunct device plays.
Germany weakness and Middle East order delays highlight regional demand sensitivity to geopolitics and sales-force stabilization efforts.
STAR-T and economic/ICU resource findings may support broader international adoption narratives, but US timing remains constrained by FDA pathway requirements.
Counterpoint
The FDA delay may be partially offset by parallel label-expansion work (DOAC removal) using existing real-world data, limiting downside to the overall commercialization timeline.
Key entities
- companyCytosorbents
CTSO reported Q1 2026 earnings and provided FDA pathway details for DrugSorb-ATR, alongside STAR-T trial efficacy and cash/burn updates.
- regulatory_programDrugSorb-ATR (de novo submission)
FDA provided clear direction requiring additional mechanistic (non-clinical) data and real-world evidence, likely delaying application to late 2026/early 2027.
- clinical_trialSTAR-T trial
Published data indicates DrugSorb-ATR reduced severe bleeding events by more than 50% in urgent cardiac surgery patients on Brilinta.
- productPuriFi pumps / HotSwap
Over 100 PuriFi pumps deployed internationally and HotSwap launch supports dosing optimization and clinician feedback.
